vs
Matador Resources Co（MTDR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Matador Resources Co的季度营收约是Revvity的1.0倍（$809.5M vs $772.1M），Matador Resources Co净利率更高（23.8% vs 12.7%，领先11.0%），Revvity同比增速更快（5.9% vs -17.2%），Revvity自由现金流更多（$161.8M vs $8.1M），过去两年Revvity的营收复合增速更高（9.0% vs 1.5%）
Matador Resources Co是一家独立能源企业，主营石油、天然气及天然气凝液的勘探、开发、生产与收购业务，核心运营区域分布在美国多个主要陆上资源盆地，产品主要供应北美能源市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MTDR vs RVTY — 直观对比
营收规模更大
MTDR
是对方的1.0倍
$772.1M
营收增速更快
RVTY
高出23.1%
-17.2%
净利率更高
MTDR
高出11.0%
12.7%
自由现金流更多
RVTY
多$153.7M
$8.1M
两年增速更快
RVTY
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $809.5M | $772.1M |
| 净利润 | $192.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 30.0% | 14.5% |
| 净利率 | 23.8% | 12.7% |
| 营收同比 | -17.2% | 5.9% |
| 净利润同比 | -10.2% | 3.9% |
| 每股收益（稀释后） | $1.54 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTDRRVTY
| Q4 25 | $809.5M | $772.1M | ||
| Q3 25 | $915.1M | $698.9M | ||
| Q2 25 | $925.7M | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $978.3M | $729.4M | ||
| Q3 24 | $860.1M | $684.0M | ||
| Q2 24 | $855.2M | $691.7M | ||
| Q1 24 | $785.3M | $649.9M |
净利润MTDRRVTY
| Q4 25 | $192.5M | $98.4M | ||
| Q3 25 | $176.4M | $46.7M | ||
| Q2 25 | $150.2M | $53.9M | ||
| Q1 25 | $240.1M | $42.2M | ||
| Q4 24 | $214.5M | $94.6M | ||
| Q3 24 | $248.3M | $94.4M | ||
| Q2 24 | $228.8M | $55.4M | ||
| Q1 24 | $193.7M | $26.0M |
毛利率MTDRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MTDRRVTY
| Q4 25 | 30.0% | 14.5% | ||
| Q3 25 | 33.4% | 11.7% | ||
| Q2 25 | 31.2% | 12.6% | ||
| Q1 25 | 38.7% | 10.9% | ||
| Q4 24 | 36.8% | 16.3% | ||
| Q3 24 | 45.6% | 14.3% | ||
| Q2 24 | 42.5% | 12.4% | ||
| Q1 24 | 40.6% | 6.8% |
净利率MTDRRVTY
| Q4 25 | 23.8% | 12.7% | ||
| Q3 25 | 19.3% | 6.7% | ||
| Q2 25 | 16.2% | 7.5% | ||
| Q1 25 | 23.9% | 6.4% | ||
| Q4 24 | 21.9% | 13.0% | ||
| Q3 24 | 28.9% | 13.8% | ||
| Q2 24 | 26.8% | 8.0% | ||
| Q1 24 | 24.7% | 4.0% |
每股收益（稀释后）MTDRRVTY
| Q4 25 | $1.54 | $0.86 | ||
| Q3 25 | $1.42 | $0.40 | ||
| Q2 25 | $1.21 | $0.46 | ||
| Q1 25 | $1.92 | $0.35 | ||
| Q4 24 | $1.71 | $0.77 | ||
| Q3 24 | $1.99 | $0.77 | ||
| Q2 24 | $1.83 | $0.45 | ||
| Q1 24 | $1.61 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.3M | $919.9M |
| 总债务越低越好 | $3.4B | — |
| 股东权益账面价值 | $5.7B | $7.3B |
| 总资产 | $11.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.60× | — |
8季度趋势，按日历期对齐
现金及短期投资MTDRRVTY
| Q4 25 | $15.3M | $919.9M | ||
| Q3 25 | $20.1M | $931.4M | ||
| Q2 25 | $10.5M | $991.8M | ||
| Q1 25 | $14.5M | $1.1B | ||
| Q4 24 | $23.0M | $1.2B | ||
| Q3 24 | $23.3M | $1.2B | ||
| Q2 24 | $15.2M | $2.0B | ||
| Q1 24 | $23.2M | $1.7B |
总债务MTDRRVTY
| Q4 25 | $3.4B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MTDRRVTY
| Q4 25 | $5.7B | $7.3B | ||
| Q3 25 | $5.5B | $7.4B | ||
| Q2 25 | $5.4B | $7.6B | ||
| Q1 25 | $5.3B | $7.6B | ||
| Q4 24 | $5.1B | $7.7B | ||
| Q3 24 | $4.9B | $7.9B | ||
| Q2 24 | $4.6B | $7.9B | ||
| Q1 24 | $4.4B | $7.8B |
总资产MTDRRVTY
| Q4 25 | $11.7B | $12.2B | ||
| Q3 25 | $11.6B | $12.1B | ||
| Q2 25 | $11.3B | $12.4B | ||
| Q1 25 | $11.1B | $12.4B | ||
| Q4 24 | $10.9B | $12.4B | ||
| Q3 24 | $10.6B | $12.8B | ||
| Q2 24 | $8.5B | $13.4B | ||
| Q1 24 | $8.2B | $13.4B |
负债/权益比MTDRRVTY
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.58× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $474.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $8.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.0% | 21.0% |
| 资本支出强度资本支出/营收 | 57.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.46× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $269.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MTDRRVTY
| Q4 25 | $474.4M | $182.0M | ||
| Q3 25 | $721.7M | $138.5M | ||
| Q2 25 | $501.0M | $134.3M | ||
| Q1 25 | $727.9M | $128.2M | ||
| Q4 24 | $575.0M | $174.2M | ||
| Q3 24 | $610.4M | $147.9M | ||
| Q2 24 | $592.9M | $158.6M | ||
| Q1 24 | $468.6M | $147.6M |
自由现金流MTDRRVTY
| Q4 25 | $8.1M | $161.8M | ||
| Q3 25 | $78.3M | $120.0M | ||
| Q2 25 | $9.6M | $115.5M | ||
| Q1 25 | $173.6M | $112.2M | ||
| Q4 24 | $45.2M | $149.8M | ||
| Q3 24 | $-1.6B | $125.6M | ||
| Q2 24 | $69.0M | $136.6M | ||
| Q1 24 | $-170.0M | $129.7M |
自由现金流率MTDRRVTY
| Q4 25 | 1.0% | 21.0% | ||
| Q3 25 | 8.6% | 17.2% | ||
| Q2 25 | 1.0% | 16.0% | ||
| Q1 25 | 17.3% | 16.9% | ||
| Q4 24 | 4.6% | 20.5% | ||
| Q3 24 | -186.5% | 18.4% | ||
| Q2 24 | 8.1% | 19.7% | ||
| Q1 24 | -21.6% | 20.0% |
资本支出强度MTDRRVTY
| Q4 25 | 57.6% | 2.6% | ||
| Q3 25 | 70.3% | 2.6% | ||
| Q2 25 | 53.1% | 2.6% | ||
| Q1 25 | 55.1% | 2.4% | ||
| Q4 24 | 54.2% | 3.4% | ||
| Q3 24 | 257.4% | 3.3% | ||
| Q2 24 | 61.3% | 3.2% | ||
| Q1 24 | 81.3% | 2.7% |
现金转化率MTDRRVTY
| Q4 25 | 2.46× | 1.85× | ||
| Q3 25 | 4.09× | 2.97× | ||
| Q2 25 | 3.34× | 2.49× | ||
| Q1 25 | 3.03× | 3.03× | ||
| Q4 24 | 2.68× | 1.84× | ||
| Q3 24 | 2.46× | 1.57× | ||
| Q2 24 | 2.59× | 2.87× | ||
| Q1 24 | 2.42× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTDR
| Oil And Gas | $702.8M | 87% |
| Natural Gas Sales | $61.3M | 8% |
| Natural Gas Midstream | $45.4M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
